Criteo Stock Price, News & Analysis

Carrefour announces its ambitious digital strategy at the Digital Day in Paris, aiming to triple its e-commerce GMV to €10bn by 2026 while adding €600m in recurring operating income. The plan, part of a €3bn investment through 2026, includes enhancing e-commerce, data-driven retail media, and digitizing financial services. Additionally, Carrefour targets carbon neutrality for e-commerce by 2030. This transformation stems from a successful four-year transition that has enhanced its digital presence significantly.

2seventy bio officially launches as an independent, publicly traded company on Nasdaq under the symbol TSVT on November 5. The company, a spin-off from bluebird bio, presents a robust pipeline in immuno-oncology cell therapies, including the recently approved ABECMA for multiple myeloma, which garnered $67 million in its first full quarter. The company is backed by approximately $442 million in cash, ensuring operational funding into 2023. With plans for innovative clinical studies in hematologic and solid tumors, 2seventy aims to transform cancer treatment.

Criteo S.A. (NASDAQ: CRTO) announced that CEO Megan Clarken will present at the Morgan Stanley European Technology, Media & Telecom Conference on November 17, 2021, at 1:15 PM Eastern Time. A live audio webcast will be available on the Company's investor relations website, with a replay option afterward. Criteo partners with over 20,000 marketers globally, leveraging extensive commerce data to enhance advertising and consumer experiences. More details can be found at www.criteo.com.

Criteo S.A. (NASDAQ: CRTO) reported strong Q3 2021 financial results, with revenue reaching $509 million, up 8% year-over-year. The company achieved a net income of $24 million, a 358% increase, resulting in diluted EPS of $0.37. Gross profit also grew by 16% to $176 million. Revenue excluding traffic acquisition costs (ex-TAC) rose 13% to $211 million. Criteo's operating cash flow remained stable at $51 million, with free cash flow decreasing to $35 million. The company raised its full-year financial guidance, reflecting ongoing business momentum and solid execution of its Commerce Media Platform strategy.

LiveRamp (NYSE: RAMP) reported a strong financial performance for Q2 fiscal 2022, with total revenue increasing by 22% to $127 million. Subscription revenue rose by 23% to $105 million, constituting 83% of total revenue. GAAP gross margin expanded to 72%, while non-GAAP gross margin reached 77%. The company achieved a record operating performance, adding 15 new direct subscription customers, bringing the total to 870. LiveRamp’s outlook for fiscal 2022 has been raised, expecting revenue of $525 million and non-GAAP operating income of $40 million.

Tilak Healthcare has successfully completed a €7 million fundraising round led by Elaia with participation from Swen Capital Partners, Matmut Innovation, and the iBionext Growth Fund. This funding will support the international rollout of its mobile vision testing platform, OdySight, which has already been adopted by nearly 20% of retinologists in France. The platform, designed for remote monitoring of visual health, aims to address the needs of the 2.2 billion people with vision impairment globally.

Criteo S.A. (NASDAQ: CRTO) is set to announce its financial results for Q3 2021 on November 3, 2021. CEO Megan Clarken and CFO Sarah Glickman will host a conference call at 8:00 AM ET, alongside Chief Product Officer Todd Parsons. U.S. callers can join at +1 855 209 8212, while international callers can access the call at +1 412 317 0788 or +33 1 76 74 05 02. The call will also be streamed live via the Criteo website, with a replay available afterward.

Shippeo, a leader in real-time transportation visibility, reported a remarkable 103% year-on-year growth in subscription revenues and a 181% net retention rate. The company welcomed numerous international brands, including Coca-Cola HBC and Nexans, expanding its global footprint. Shippeo's employee count has increased to over 230, with plans to double its workforce by the end of 2021. The company maintains a 0% customer churn rate, emphasizing enhanced product offerings and partnerships with leading supply chain firms.

bluebird bio has announced a tax-free spin-off of its oncology programs into 2seventy bio, with a completion timeline of early November 2021. Shareholders will receive 1 share of 2seventy bio for every 3 shares of bluebird bio owned. The company expects approximately $1.0B in cash reserves at the time of separation, funding 2seventy bio with $480M. Two new board members, Najoh Tita-Reid and Sarah Glickman, have been appointed to strengthen leadership. The separation is designed to enhance operational focus and shareholder value.